CapsoVision (CV) Preferred Stock Liabilities (2024 - 2025)

CapsoVision's (CV) quarterly Preferred Stock Liabilities came in at $143.6 million in Q2 2025, up 11.66% year-on-year from $128.6 million in Q2 2024, and little changed quarter-over-quarter from $143.6 million in Q4 2024.

CapsoVision (CV) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends

CapsoVision has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $143.6 million for Q2 2025.

  • Preferred Stock Liabilities for Q2 2025 came in at $143.6 million, up 11.66% year-over-year; the trailing twelve-month figure through Jun 2025 was $143.6 million (up 11.66% YoY), and the FY2024 annual result was $143.6 million, changed N/A from the prior year.
  • Preferred Stock Liabilities came in at $143.6 million for Q2 2025 at CapsoVision, roughly flat from $143.6 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $143.6 million in Q4 2024 to a low of $128.6 million in Q2 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn -
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn -
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn -
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn -
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn -
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn -
10 CapsoVision 161.82 Mn 151.71 Mn 1.95 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2025 143.63 Mn
Dec 31, 2024 143.63 Mn
Sep 30, 2024 138.63 Mn
Jun 30, 2024 128.63 Mn